The benefit of abemaciclib has persisted since the end of the 2-year abemaciclib treatment, as evidenced by the continuous separation of the Kaplan-Meier curves for the two treatment groups, showing an increasing trend.
← all excerpts
A narrative review: research progress of adjuvant intensive endocrine therapy for early breast cancer.
1
—
—